Monitor the October 15 KOL event for any disclosed efficacy or safety data from the PDS0301 Phase 2 mCRC cohort. Positive data could serve as a catalyst, but the filing itself contains no new clinical results.
Price Chart
Executive Summary
PDS Biotechnology filed an 8-K announcing a virtual KOL event on October 15, 2026, to discuss Phase 2 clinical outcomes for PDS0301 in advanced colorectal cancer with liver metastases. The event features an NCI investigator and focuses on MSS/pMMR patients, a population where immunotherapy has been largely ineffective. No new clinical data or financial results were disclosed in this filing.
Key Facts
- Virtual KOL event scheduled for October 15, 2026 at 8:00 AM ET
- Event will discuss PDS0301 Phase 2 trial outcomes in advanced liver-associated cancers, focusing on mCRC cohort
- PDS0301 is an investigational IL-12 immunocytokine targeting necrotic DNA within tumors
- Trial targets second and third line unresectable MSS or pMMR colorectal liver metastases
- No financial data, clinical results, or guidance provided in the filing
Financial Impact
No financial impact disclosed; event is educational and non-material
Risk Factors
- No new clinical data disclosed — event may not produce material stock-moving information
- PDS0301 is still investigational with no approved products; regulatory and development risks remain
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-038728 |
| Document: ef20083341_ex99-1.htm | 0001140361-26-038728 |
| Document: 0001140361-26-038728-index-headers.html | 0001140361-26-038728 |
| Document: 0001140361-26-038728-index.html | 0001140361-26-038728 |
| Document: 0001140361-26-038728.txt | 0001140361-26-038728 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 3 | $1.24 $1.16 | ▼ −6.45% | ▼ −5.27% | $1.07 (−14.11%) |
Oct 20, 2026 6d ago | 8-K | $1.24 $1.16 | ▼ −6.45% | ▼ −5.27% | $1.07 (−14.11%) |
Oct 20, 2026 6d ago | 8-K | $0.9605 $1.24 | ▲ +29.10% | ▲ +28.57% | $1.07 (+10.88%) |
Oct 14, 2026 12d ago | S-3 | $1.30 $1.13 | ▲ +13.08% | ▲ +11.97% | $1.07 (+18.08%) |
Oct 6, 2026 20d ago | 8-K | $1.05 $1.07 | ▲ +1.91% | ▲ +2.15% | $1.07 (+1.91%) |
Sep 22, 2026 4w ago | 8-K | $0.9100 $0.8239 | ▼ −9.46% | ▼ −8.74% | $1.07 (+17.03%) |
Sep 22, 2026 4w ago | Press Release | $0.9100 $0.8239 | ▼ −9.46% | ▼ −8.74% | $1.07 (+17.03%) |
Sep 21, 2026 5w ago | SC 13D | $0.9100 $0.8240 | ▼ −9.45% | ▼ −8.73% | $1.07 (+17.03%) |
Sep 4, 2026 7w ago | 8-K | $0.3000 $0.2930 | ▲ +2.33% | ▲ +1.87% | $1.07 (−255.00%) |
Aug 19, 2026 9w ago | 8-K | $0.2089 $0.2185 | ▲ +4.60% | ▲ +4.19% | $1.07 (+409.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers